Objective: To conduct a systematic review on the association between tetanus vaccination and the risk of multiple sclerosis (MS). Methods: The authors searched the databases Medline, LILACS, EMBASE, and Science Citation Index including the period 1966 to September 1, 2005. Eligible studies had to meet the following inclusion criteria: presentation of original data, case-control or cohort design, physician-confirmed diagnosis of MS as the outcome of interest, attempt to ascertain vaccinations in a period before the diagnosis, and report of an association measure between tetanus vaccination and incidence of MS, and its 95% CI or enough information to compute it. Study specific log ORs were weighted by the inverse of their variances to obtain a pooled estimate and its 95% CI. Results: The OR of MS associated with history of tetanus vaccination was 0.67 (95% CI: 0.55 to 0.81). There was little indication of heterogeneity of results across studies. Conclusion: Tetanus vaccination is associated with a lower risk of multiple sclerosis.
Tetanus immunity, either naturally acquired or vaccine-induced, has been proposed to protect against the development of multiple sclerosis (MS). 1 This hypothesis is supported by the findings of two recent prospective studies, which found a lower risk of MS after tetanus vaccination. 2, 3 Because the tetanus toxoid contains a universal human T-helper cell epitope, a strong effect of the tetanus toxoid on the pathogenesis of MS could have implications not only for MS treatment but also for the development of safer vaccines for other neurologic disorders. 4, 5 We summarized the epidemiologic evidence and quantified the magnitude of the association between tetanus vaccination and MS risk.
Methods. We identified potentially eligible studies through a computerized Medline search including the period 1966 to September 1, 2005 . The following search algorithm was applied to Medical Subjects Headings and free text words: (tetanus OR vaccination OR vaccine) AND (MS) AND (case-control OR casereferent OR retrospective OR cohort* OR follow-up OR incidenc* OR prospective or epidemiolog*). Similar search strategies were applied to the databases LILACS (Latin America and Caribbean), EMBASE (Europe), and Science Citation Index. We also examined the references in the articles retrieved through the computerized search, and other published articles on the epidemiology of MS.
Eligible studies had to meet the following inclusion criteria: presentation of original data, case-control or cohort design, physician-confirmed MS diagnosis as the outcome of interest, attempt to ascertain vaccinations in a period before the MS diagno-sis, and report of an association measure between tetanus vaccination and MS incidence, and its 95% CI or enough information to compute it.
We developed a structured questionnaire to record the following data from the individual studies: design (case-control, casecontrol nested in a well defined cohort, cohort), number of participants (cases and controls, or cases and cohort size), type of controls (friends or relatives, patients with other diseases, community members or neighbors, combination of these groups), country, year of publication, assessment of vaccination (self-reported, independently ascertained), adjustment variables, and association measure between tetanus vaccination and MS risk. When not enough information was available in the published report to compute the association measure and its 95% CI, we contacted the authors of the study.
Statistical analysis. Study-specific log ORs were weighted by the inverse of their variances to obtain a pooled association measure estimate and its 95% CI. Random effects pooled estimates were virtually identical to the fixed effects estimates that we present.
We checked for heterogeneity using the parametric bootstrap (1,000 replications) version of the DerSimonian and Laird Q test statistic implemented in the software by Takkouche et al. 6 We also computed the I 2 statistic proposed by the Cochrane Collaboration. 7 We assessed potential publication bias by using sensitivity analyses and a funnel plot.
Results.
Nine case-control studies, including 963 cases and 3,126 controls, fulfilled the inclusion criteria. 2, 3, [8] [9] [10] [11] [12] [13] [14] Another case-control study was excluded because of lack of information to compute an OR. 15 The table describes the characteristics of the nine studies included, which were conducted in six countries and published between 1968 and 2004.
The pooled OR of MS and tetanus vaccination was 0.67 (95% CI: 0.55, 0.81) (figure 1). There was little indication of heterogeneity of results across studies (I 2 ϭ 2.5%, p value for Q statistic ϭ 0.41).
The pooled OR (95% CI) was 0.63 (0.48, 0.82) when the analysis was restricted to the three studies 2,3,13 that adjusted for age and sex, 0.60 (0.45, 0.79) when the analysis was restricted to the two studies that were nested in a well defined cohort, 2,3 and 0.59 (0.46, 0.77) when the analysis was restricted to the three studies 2,3,8 that attempted to ascertain vaccinations before first symptoms (as opposed to diagnosis) of MS. The pooled OR from the two studies 2,3,14 that reported the association with recent tetanus vaccination (Յ5 years) was 0.57 (95% CI 0.38, 0.85).
To evaluate the possibility of publication bias, we recalculated our pooled estimate under the following extreme assumptions: 1) the studies listed in the table are only half of the studies on tetanus vaccination and MS risk ever conducted; studies in the other half were never published, 2) all unpublished studies found null associations (i.e., OR ϭ 1) between tetanus vaccination and MS, and 3) the unpublished studies included, on average, as many cases and controls as the published ones. Under these assumptions, the pooled OR (95% CI) for MS and tetanus vaccination was 0.82 (0.71, 0.94). Also, although the number of studies was relatively low, a funnel plot did not suggest substantial publication bias (figure 2) because the preci- sion of the study-specific OR estimates increased as the study sample size increased.
Discussion. Tetanus vaccination is associated with a one-third reduction in MS risk vs no vaccination. It is unlikely that this lower risk is the result of publication bias because our sensitivity analysis showed that the association would persist even under extreme assumptions regarding the number and size of unpublished studies. The finding cannot be fully explained by recall or selection bias in the individual studies because the magnitude of the pooled association did not materially change when the meta-analysis was restricted to studies that were nested in a well defined cohort and that used vaccination history recorded before the onset of MS. An alternative explanation to a protective effect of tetanus vaccination on MS risk is that tetanus vaccination may be a marker for an unknown protective factor. Because only an extremely protective factor would explain the magnitude of the inverse association found between tetanus vaccination and MS risk, this alternative explanation encourages the search for such factor among the exposures strongly associated with tetanus vaccination.
Since tetanus immunization is almost universal in Western countries, the results of our meta-analysis suggest that the vaccine may prevent or delay MS during a post-immunization period of unknown duration. Further epidemiologic research is warranted to determine the role of the timing of immunization and the number of doses. Two other epidemiologic reports not included in our meta-analysis offer additional support for the association between tetanus vaccination and MS. First, an ancillary analysis of the Vaccine Safety Datalink project found a dose-response relationship between tetanus vaccination and risk of MS. Compared with nonvaccinated individuals, the OR (95% CI) of MS was 0.63 (0.46, 0.88) for individuals who received one dose of tetanus vaccination, 0.42 (0.26, 0.69) for those who received two doses, and 0.23 (0.11, 0.50) for those who received Ͼ2 doses. 16 Second, the Vaccines in Multiple Sclerosis Study reported a lower risk of MS relapses after the administration of tetanus vaccination, particularly when administered in combination with diphtheria or poliovirus immunizations. 17 Compared with no tetanus vaccination, the relative risk (95% CI) of relapse was 0.75 (0.23, 2.46) for exposure to tetanus vaccination in the 2 months preceding a relapse, and 0.22 (0.05, 0.99) for exposure to combined tetanus vaccination in the 2 months preceding a relapse.
The biologic mechanisms by which the tetanus vaccine may reduce the risk of MS are unknown but, interestingly, the tetanus toxoid contains a peptide determinant that can bind to a wide range of human MHC class II molecules, a so-called "universal" helper T cell epitope. 4 (In fact, the tetanus toxoid is commonly conjugated with self-antigens in experimental vaccines to amplify the immune response because it generates strong T-helper activation, resulting in accelerated immunoglobulin class switch to IgG. 4, 18, 19 ) Vaccination with T cell receptor (TCR) peptides has been shown to shift the T helper cell response from Type 1 (Th1, pro-inflammatory cytokines) to Type 2 (Th2, anti-inflammatory cytokines) by activating regulatory T cells capable of inhibiting myelin reactive T cells. 5 These regulatory T cells recognize processed TCR peptides presented by the MHC class II molecules on the surface of activated Th1 cells, and then can produce Th2-type immunomodulatory cytokines that downregulate the activated Th1 cells as well as other activated myelin reactive Th1 cells within the CNS. This mechanism, referred to as bystander suppression, probably explains why TCR vaccines prevent and reverse symptoms in rodents with experimental autoimmune encephalomyelitis (an animal model of MS), and boost human regulatory Th2-type TCR reactive T cells, which in turn decrease circulating myelin reactive Th1 cells. 20, 21 Although most of these studies are of short duration, we can speculate that the tetanus toxoid may also lead to a shift from a Th1 to Th2 response to environmental stimuli. Thus, under the assumption that a shift from Th1 to Th2 is beneficial for MS, immunizing with the tetanus toxoid could be a promising approach for the treatment and prevention of MS and other Th1 cell mediated autoimmune disorders. 
